Macrophages co-loaded with drug-associated and superparamagnetic nanoparticles for triggered drug release by alternating magnetic fields.

Two features of macrophages make them attractive for targeted transport of drugs: they efficiently take up a broad spectrum of nanoparticles (NPs) and, by sensing cytokine gradients, they are attracted to the sites of infection and inflammation. To expand the potential of macrophages as drug carriers, we investigated whether macrophages could be simultaneously coloaded with different types of nanoparticles, thus equipping individual cells with different functionalities. We used superparamagnetic iron oxide NPs (SPIONs), which produce apoptosis-inducing hyperthermia when exposed to an alternating magnetic field (AMF), and co-loaded them on macrophages together with drug-containing NPs (inorganic-organic nanoparticles (IOH-NPs) or mesoporous silica NPs (MSNs)).

Inorganic-organic hybrid nanoparticles with carbonate-triggered emission-colour-shift.

(Eu[PTC])(Eu[TREN-1,2-HOPO]) inorganic-organic hybrid nanoparticles (IOH-NPs) contain Eu, tris[(1-hydroxy-2-oxo-1,2-dihydropyridine-6-carboxamido)ethyl]amine (TREN-1,2-HOPO) and perylene-3,4,9,10-tetracarboxylate (PTC). The IOH-NPs are prepared in water and exhibit a rod-type shape, with a length of 60 nm and a diameter of 5 nm. Particle size and chemical composition are examined by different methods (SEM, DLS, FT-IR, TG, C/H/N analysis).

High-porosity Pt-CeO nanosponges as oxidation catalyst.

Pt-CeO nanosponges (1 wt% Pt) with high surface area (113 m g), high pore volume (0.08 cm g) and small-sized Pt nanoparticles (1.8 ± 0.

Crown-Ether Coordination Compounds of Europium and 24-Crown-8.

Crown-ether coordination compounds of europium(II/III) and the crown ether (CHO) (24-crown-8, 24c8) are prepared, aiming at novel compounds, structures, and coordination modes as well as potential luminescence properties. By reacting EuCl, EuI, or EuCl with 24c8 or its derivatives in ionic liquids, the novel compounds [BuMeN][Eu(II)(NTf)] (), [BMIm][EuI] (), [EuCl(dibenzo-18c6)] (), [EuI(dibenzo-24c8)] (), [(Eu(III)Cl)(CHO)](24c8) (), and [Eu(III)Cl(24c8)]I () are obtained (BMIm: 1-butyl-3-methylimidazolium; EMIm: 1-ethyl-3-methylimidazolium). Based on different reaction conditions, different coordinative modes including the absence of the crown ether in the product (, ), splitting of the crown ether (), and coordination of 24c8 via six of eight oxygen atoms () and, finally, via all oxygen atoms () are observed.

A Comparative Pharmacokinetics Study of Orally and Intranasally Administered 8-Nitro-1,3-benzothiazin-4-one (BTZ043) Amorphous Drug Nanoparticles.

BTZ043 is an 8-nitro-1,3-benzothiazin-4-one with potency against multidrug-resistant . Low solubility and hepatic metabolism are linked to poor oral bioavailability. Amorphous drug nanoparticles (ADN) were formulated to improve the bioavailability.